Summary
ACE inhibitors (ACEIs) are commonly prescribed for hypertension, a global risk factor for cardiovascular disease. Their primary side effect is a dry cough which affects 5-35% of users. As clinical guidelines recommend switching those experiencing cough to an angiotensin-II receptor blocker, we have used this switch as a proxy for ACEI-induced cough. Through a two-stage multi-ancestry genome-wide association study, including up to 7,030 cases and 39,921 controls, we identify five independent genome-wide significant associations implicating six protein-coding genes, including INHBC, KCNIP4, NTSR1 and PREP which encode proteins involved in the nervous system. We also observe genetic overlap between ACEI-induced cough and chronic dry cough through genetic correlation and phenome-wide association studies. In line with existing hypotheses, our findings suggest a neurological basis for the pathology of ACEI-induced cough, particularly the role of proinflammatory mediators in sensory airway sensitivity and cough reflex modulation, and shared biological mechanisms with chronic dry cough.
Competing Interest Statement
RP and CJ report funding from Orion Pharma outside of the submitted work. LVW has held research grants from GlaxoSmithKline (as principal investigator) and Orion Pharma (as co-investigator), unrelated to current work, and reports consultancy for Galapagos. MDT has research collaborations with Orion Pharma and GlaxoSmithKline unrelated to the current work.
Funding Statement
KC was supported by the University of Leicester (College of Life Sciences) and Health Data Research UK. CJ held a Medical Research Council Clinical Research Training Fellowship (MR/P00167X/1). LVW holds a GSK/Asthma + Lung UK Chair in Respiratory Research (C17-1). MDT holds a Wellcome Trust Investigator Award (WT202849/Z/16/Z), which has partially supported EXCEED, and NIHR Senior Investigator Award (NIHR201371). CB was supported by a UKRI Innovation Fellowship at Health Data Research UK (MR/S003762/1). This study used data from the Extended Cohort for E-health, Environment and DNA (EXCEED) study. EXCEED is supported by the University of Leicester, the National Institute for Health and Care Research (NIHR) Leicester Respiratory Biomedical Research Centre, the Wellcome Trust (WT 202849), and Cohort Access fees from studies funded by the Medical Research Council (MRC), Biotechnology and Biological Sciences Research Council, NIHR, the UK Space Agency, and GlaxoSmithKline. It was previously supported by MRC grant G0902313. EXCEED is supported by BREATHE - The Health Data Research Hub for Respiratory Health (UKRI_PC_19004) in partnership with SAIL Databank. BREATHE is funded through the UK Research and Innovation (UKRI) Industrial Strategy Challenge Fund and delivered through Health Data Research UK. The research was partially supported by the NIHR Leicester Biomedical Research Centre and the NIHR Nottingham Biomedical Research Centre; views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This research was funded in whole, or in part, by the Wellcome Trust. This work was supported by the University of Leicester and Health Data Research UK, an initiative funded by UKRI, Department of Health and Social Care (England) and the devolved administrations, and leading medical research charities.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for use of EHR in the EXCEED study was awarded by Leicester Central REC 13/EM/0226, IRAS:129201. The UK Biobank genetic and phenotypic data were obtained under UK Biobank Application 59822.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵5 Lead contact
Data Availability
UK Biobank (https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access) and EXCEED (https://exceed.org.uk/research/) individual-level data are available to approved researchers upon application or data access request. GWAS summary statistics from the eMERGE Network study (Stage 2) are available from the respective study authors. GWAS summary statistics from the discovery (Stage 1) analysis are being deposited at the NHGRI-EBI GWAS Catalog (https://www.ebi.ac.uk/gwas/) and accession numbers will be added as soon as they are available. The phenotyping algorithm is publicly available (https://doi.org/10.5281/zenodo.6780065); scripts used to run additional analyses are available upon request to the lead contact.
